Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 53
Filtrar
Mais filtros

Tipo de documento
Intervalo de ano de publicação
1.
Animal ; 13(12): 2932-2938, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31155019

RESUMO

Vitamins play an essential role in broiler nutrition. They are fundamental for normal metabolic and physiological process, and their requirements for poultry are not fixed and can be affected by multiple factors. In contrast, mycotoxins are a challenging issue because they hinder performance and the immune system. Vitamin supplementation above minimum requirements would permit improvement in productive potential, health, bone and meat quality in a situation of mycotoxin challenge. The objective of this study was to determine the influence of optimum vitamin nutrition in diets contaminated with aflatoxin in broilers from 1 to 44 days of age. A total of 1800 Cobb 500 male chicks were randomized to 15 sets of eight treatment groups, each containing 15 birds using a 2 × 2 × 2 factorial design (commercial vitamin levels and high vitamin levels, two levels of aflatoxin - 0 and 0.5 ppm with binder levels of 0 and 10 000 mg/kg). The mash diets were corn and soybean meal based, formulated according to commercial practices. Feed intake, weight gain and feed conversion were analyzed for birds from 1 to 44 days of age. To determine carcass characteristics (carcass yield, breast yield and leg yield) and black bone syndrome, two birds were slaughtered from each group at 45 days. Other analyses included breast tenderness, water loss by dripping and malonaldehyde concentrations. The results demonstrated that broilers that were fed high levels of vitamins showed better weight gain, feed conversion, carcass yield and breast yield than broilers that were fed diets with commercial vitamin levels (P < 0.05); also, broilers that were fed diets containing 0.5 ppm aflatoxin had lower weight gain, carcass yield and breast yield (P < 0.05). The use of 10 000 mg/kg of binder improved (P < 0.05) feed conversion throughout the rearing period. We conclude that aflatoxin negatively affects performance and carcass yield; however, feeding optimum vitamin nutrition improved these performance traits.


Assuntos
Aflatoxinas/efeitos adversos , Doenças Ósseas/veterinária , Galinhas , Carne/análise , Doenças das Aves Domésticas/epidemiologia , Vitaminas/metabolismo , Aflatoxinas/administração & dosagem , Ração Animal/análise , Fenômenos Fisiológicos da Nutrição Animal , Animais , Doenças Ósseas/epidemiologia , Doenças Ósseas/etiologia , Brasil/epidemiologia , Galinhas/crescimento & desenvolvimento , Galinhas/fisiologia , Dieta/veterinária , Suplementos Nutricionais/análise , Masculino , Doenças das Aves Domésticas/etiologia , Distribuição Aleatória , Vitaminas/administração & dosagem
2.
J Steroid Biochem Mol Biol ; 180: 35-40, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29247782

RESUMO

The objectives of this study were to: 1) Determine the impact of varying baseline serum 25OHD on increase in vitamin D concentrations after daily supplementation with vitamin D and calcium (1000 IU + 500 mg respectively) for six months in school-children from a semi-rural setting 2) Test the efficacy of daily vitamin D-calcium supplementation on improvement in serum vitamin D concentrations to ≥75 nmol/L. Data collected from 106 subjects (58 boys, 48 girls), aged 6-12 years, included anthropometric measures like height and weight, body composition analysis, three one-day dietary recalls and sunlight exposure (by questionnaire). Blood was collected at baseline and endline and estimated for serum vitamin D by ELISA technique using standard kits. Classification of Vitamin D status was performed according to the 2011 Endocrine Society Practice Guidelines: vitamin D deficiency - <50 nmol/L; insufficiency - 50.0-74.9 nmol/L; sufficiency - ≥75 nmol/L. Statistical analysis was performed using SPSS software. Mean baseline serum vitamin D concentration was 59.7 ±â€¯11.2 nmol/L; this rose to 79.8 ±â€¯23.3 nmol/L with no significant differences between genders at the two time-points. Inverse relationship was obtained between baseline serum 25(OH)D concentrations and change in serum concentrations after supplementation, implying that with increasing baseline serum concentrations of 25(OH)D, increase in vitamin D levels post supplementation were significantly lower (r = - 0.96, p < 0.0001). Greatest benefit of change in serum vitamin D concentrations after supplementation was experienced by children with basal concentrations of <45 nmol/L. Daily vitamin D supplementation was effective in improving serum 25(OH)D to ≥75 nmol/L in 44% of children. Significantly higher percentage of children who were deficient at baseline (64%) were able to attain serum concentrations of ≥75 nmol/L as compared to children who were vitamin D insufficient (43%) (p < 0.001). Thus, daily supplementation with 1000 IU of vitamin D along with 500 mg of calcium helped in improving serum vitamin D concentrations to ≥75 nmol/L. Children who were vitamin D deficient particularly experienced these benefits.


Assuntos
Biomarcadores/sangue , Doenças Ósseas/sangue , Deficiência de Vitamina D/sangue , Vitamina D/análogos & derivados , Vitamina D/administração & dosagem , Doenças Ósseas/tratamento farmacológico , Doenças Ósseas/epidemiologia , Criança , Método Duplo-Cego , Feminino , Humanos , Índia/epidemiologia , Masculino , População Rural , Instituições Acadêmicas , Vitamina D/sangue , Deficiência de Vitamina D/tratamento farmacológico , Deficiência de Vitamina D/epidemiologia , Vitaminas/administração & dosagem
3.
Semin Pediatr Neurol ; 24(4): 301-309, 2017 11.
Artigo em Inglês | MEDLINE | ID: mdl-29249510

RESUMO

Antiseizure medications and dietary therapies have associated effects on the endocrine system. We provided an overview of the relationship between epilepsy treatment and bone health in children with epilepsy. Additionally, we discussed the effects of epilepsy treatment on other endocrine systems including thyroid function, growth, reproduction, and weight. The effect of epilepsy on bone health is multifactorial; there are direct and indirect effects of medication and dietary treatments as well as a decrease in physical activity, decreased sunlight exposure, decreased vitamin D levels, and additional comorbidities. Some medications have a greater effect on vitamin D and bone health than others, however all antiseizure medical treatments are associated with lower vitamin D levels in pediatric patients. We have provided practical suggestions for vitamin D surveillance in children with epilepsy as well as replacement strategies. Children with epilepsy have an increased likelihood of additional endocrine disorders including subclinical hypothyroidism, decreased growth, weight abnormalities, reproductive and sexual dysfunction. To a great extent, this is medication specific. Though more studies are needed to elucidate optimal treatment and monitoring of bone health and other endocrinopathies in children with epilepsy, it is critical that caregivers pay close attention to these issues to provide optimal comprehensive care to their patients.


Assuntos
Doenças Ósseas/complicações , Doenças Ósseas/fisiopatologia , Doenças do Sistema Endócrino/complicações , Doenças do Sistema Endócrino/fisiopatologia , Epilepsia/complicações , Epilepsia/fisiopatologia , Doenças Ósseas/epidemiologia , Osso e Ossos/efeitos dos fármacos , Osso e Ossos/fisiopatologia , Criança , Comorbidade , Doenças do Sistema Endócrino/epidemiologia , Epilepsia/tratamento farmacológico , Epilepsia/epidemiologia , Humanos
4.
J Clin Endocrinol Metab ; 102(7): 2321-2328, 2017 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-28379394

RESUMO

Context: Vitamin D "insufficiency" and "deficiency" are defined as serum 25-hydroxyvitamin D [25(OH)D] levels <75 and <30 nmol/L, respectively. We aimed to determine whether these values signal hypocalcemia and hypophosphatemia, secondary hyperparathyroidism, high bone remodeling, low areal bone mineral density (aBMD), microstructural deterioration, or reduced matrix mineralization density (MMD) and so suggest whether bone fragility is present. Methods: Concentrations of 25(OH)D, calcium, phosphate, creatinine, and parathyroid hormone (PTH) were measured in 11,855 participants. Serum C-terminal telopeptide of type 1 collagen, procollagen type 1 N-terminal propeptide (P1NP), aBMD, and distal radius microstructure and MMD were measured in a second subset of 150 participants. Results: A breakpoint for calcium, PTH, and alkaline phosphatase was identified at a threshold 25(OH)D level <30 nmol/L. There was no plateau beyond 75 nmol/L. In the subgroup with measurements of bone morphology, no associations were detectable between serum 25(OH)D concentration, aBMD, trabecular density, cortical porosity, or MMD. Among 1439 participants with serum 25(OH)D <30 nmol/L, 6.1% had low serum calcium, 3.4% had low serum phosphate, 6.1% had high alkaline phosphatase, and 34.2% had elevated PTH. Most participants did not have any abnormalities. Conclusion: At a 25(OH)D threshold of ≤30 nmol/L, abnormalities in biochemical features support the notion of a "deficiency" state predisposing to bone disease. However, no deleterious effects were found in participants within an insufficiency threshold of a 25(OH)D level of 30 to 75 nmol/L, which challenges the rationale justifying vitamin D supplementation in these individuals.


Assuntos
Doenças Ósseas/etiologia , Deficiência de Vitamina D/complicações , Vitamina D/análogos & derivados , Adulto , Idoso , Fosfatase Alcalina/sangue , Densidade Óssea/fisiologia , Doenças Ósseas/sangue , Doenças Ósseas/epidemiologia , Doenças Ósseas/fisiopatologia , Remodelação Óssea/fisiologia , Cálcio/sangue , Estudos de Coortes , Feminino , Taxa de Filtração Glomerular , Humanos , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Fosfatos/sangue , Vitória/epidemiologia , Vitamina D/sangue , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/epidemiologia , Deficiência de Vitamina D/fisiopatologia
5.
Nutr Clin Pract ; 32(2): 258-265, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27589260

RESUMO

BACKGROUND: Previous studies have noticed the high incidence of suboptimal vitamin D (VtD) status and bone loss in short bowel syndrome (SBS) with parenteral nutrition (PN) dependence. However, limited data have focused on adult SBS without PN dependence. Therefore, our objective was to investigate the incidence and risk factors of suboptimal VtD status and bone loss in adult SBS even after weaning off PN. MATERIALS AND METHODS: We performed a prospective study of 60 adult patients with SBS. Serum 25-hydroxyvitamin D (25-OHD) was measured by radioimmunoassay. Bone mineral density (BMD) was measured using dual-energy x-ray absorptiometry (DEXA). Medical records and various laboratory parameters were collected in all participants. RESULTS: Suboptimal VtD status was identified in all individuals, including 3 (5.0%) with VtD insufficiency and 57 (95.0%) with VtD deficiency. Residual small bowel length (B, 0.072, P = .001) and duration of SBS (B, -0.066, P = .020) were both significantly correlated with suboptimal VtD levels. Overall, only 2 patients presented a normal BMD; osteopenia and osteoporosis were noted in 41 (68.3%) and 17 (28.3%) individuals, respectively. Low 25-OHD concentration was associated with a decreased BMD (B, 0.065, P = .029). There were no other demographic characteristics or clinical examinations associated with suboptimal VtD levels and bone loss. CONCLUSION: Suboptimal VtD status and bone loss were common in adult SBS even after weaning off PN. Despite routine oral VtD supplementation, most patients did not achieve satisfactory status. This emphasizes the critical importance of routine surveillance of 25-OHD and BMD, as well as consideration of alternative methods of supplementation after weaning off PN.


Assuntos
Doenças Ósseas/sangue , Doenças Ósseas/epidemiologia , Síndrome do Intestino Curto/sangue , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/epidemiologia , Vitamina D/sangue , Absorciometria de Fóton , Adulto , Densidade Óssea , Doenças Ósseas/etiologia , Suplementos Nutricionais , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Estado Nutricional , Nutrição Parenteral/efeitos adversos , Prevalência , Estudos Prospectivos , Fatores de Risco , Síndrome do Intestino Curto/terapia , Vitamina D/administração & dosagem , Deficiência de Vitamina D/etiologia , Adulto Jovem
6.
Breast Cancer Res Treat ; 161(3): 501-513, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27915435

RESUMO

PURPOSE: The majority of breast cancer patients receive endocrine therapy, including aromatase inhibitors known to cause increased bone resorption. Bone-related biomarkers at the time of breast cancer diagnosis may predict future risk of osteoporosis and fracture after endocrine therapy. METHODS: In a large population of 2,401 female breast cancer patients who later underwent endocrine therapy, we measured two bone remodeling biomarkers, TRAP5b and BAP, and two bone regulating biomarkers, RANKL and OPG, in serum samples collected at the time of breast cancer diagnosis. We analyzed these biomarkers and their ratios with patients' demographic, lifestyle, clinical tumor characteristics, as well as bone health history. RESULTS: The presence of bone metastases, prior bisphosphonate (BP) treatment, and blood collection after chemotherapy had a significant impact on biomarker levels. After excluding these cases and controlling for blood collection time, several factors, including age, race/ethnicity, body mass index, physical activity, alcohol consumption, smoking, and hormonal replacement therapy, were significantly associated with bone biomarkers, while vitamin D or calcium supplements and tumor characteristics were not. When prior BP users were included in, recent history of osteoporosis and fracture was also associated. CONCLUSIONS: Our findings support further investigation of these biomarkers with bone health outcomes after endocrine therapy initiation in women with breast cancer.


Assuntos
Doenças Ósseas/complicações , Doenças Ósseas/metabolismo , Remodelação Óssea , Neoplasias da Mama/complicações , Neoplasias da Mama/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores , Biomarcadores Tumorais , Densidade Óssea , Doenças Ósseas/epidemiologia , Doenças Ósseas/patologia , Neoplasias Ósseas/metabolismo , Neoplasias Ósseas/secundário , Neoplasias da Mama/diagnóstico , Exercício Físico , Feminino , Fraturas Ósseas/epidemiologia , Fraturas Ósseas/etiologia , Fraturas Ósseas/metabolismo , Humanos , Estilo de Vida , Pessoa de Meia-Idade , Gradação de Tumores , Estadiamento de Neoplasias , Osteoporose/epidemiologia , Osteoporose/etiologia , Osteoporose/metabolismo , Pós-Menopausa , Pré-Menopausa , Fatores de Risco
7.
Ann N Y Acad Sci ; 1368(1): 82-94, 2016 03.
Artigo em Inglês | MEDLINE | ID: mdl-27186941

RESUMO

Patients with non-transfusion-dependent thalassemia (NTDT) experience a wide array of clinical complications despite their independence from frequent, regular red blood cell (RBC) transfusions. According to the current understanding of NTDT, these clinical complications stem from the interaction of multiple pathophysiological factors: ineffective erythropoiesis, iron overload, and hypercoagulability. The state of chronic anemia and hypoxia-resulting from ineffective erythropoiesis and hemolysis-leads to the expansion of the erythroid marrow and extramedullary hematopoiesis. The chronic ineffective erythropoiesis also triggers increased intestinal iron absorption and deposition in the liver and endocrine glands despite the lack of transfusional iron load. Patients with NTDT also have a higher incidence of thromboembolic disease, pulmonary hypertension, and silent cerebral ischemia. The treatment of NTDT relies on occasional or more frequent blood transfusions for certain indications (severe infection, pregnancy, and surgery), iron chelation therapy, splenectomy, and hydroxyurea. Splenectomy is no longer routinely performed in all patients with NTDT in light of its association with increased risk of NTDT-related complications. This review focuses on the clinical morbidities associated with NTDT, summarizes the mainstays of treatment, and sheds light on future therapeutic directions in the field.


Assuntos
Transfusão de Sangue , Talassemia/epidemiologia , Talassemia/terapia , Doenças Ósseas/epidemiologia , Doenças Ósseas/metabolismo , Doenças Ósseas/terapia , Eritropoese/efeitos dos fármacos , Eritropoese/fisiologia , Humanos , Absorção Intestinal/efeitos dos fármacos , Absorção Intestinal/fisiologia , Quelantes de Ferro/farmacologia , Quelantes de Ferro/uso terapêutico , Sobrecarga de Ferro/epidemiologia , Sobrecarga de Ferro/metabolismo , Sobrecarga de Ferro/terapia , Morbidade , Talassemia/metabolismo , Trombose/epidemiologia , Trombose/metabolismo , Trombose/terapia
8.
J Epidemiol ; 26(2): 57-63, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26499132

RESUMO

BACKGROUND: The prevalence of brick tea-type fluorosis is high in Tibet because of the habit of drinking brick tea in this region. Brick tea-type fluorosis has become an urgent public health problem in China. METHODS: A cross-sectional survey was conducted to investigate prevalence of brick tea-type fluorosis in all districts of Tibet using a stratified cluster sampling method. Dental fluorosis in children aged 8-12 years and clinical skeletal fluorosis in adults were diagnosed according to the national criteria. A total of 423 children and 1320 adults participated in the study. Samples of drinking water, brick tea, brick tea infusion (or buttered tea), and urine were collected and measured for fluoride concentrations by the fluoride ion selective electrode method. RESULTS: The fluoride level in all but one of the brick tea samples was above the national standard. The average daily fluoride intake from drinking brick tea in all seven districts in Tibet was much higher than the national standard. The prevalence of dental fluorosis was 33.57%, and the prevalence of clinical skeletal fluorosis was 46.06%. The average daily fluoride intake from drinking brick tea (r = 0.292, P < 0.05), urine fluoride concentrations in children (r = 0.134, P < 0.05), urine fluoride concentrations in adults (r = 0.162, P < 0.05), and altitude (r = 0.276, P < 0.05) were positively correlated with the prevalence of brick tea-type fluorosis. Herdsmen had the highest fluoride exposure and the most severe skeletal fluorosis. CONCLUSIONS: Brick tea-type fluorosis in Tibet is more serious than in other parts of China. The altitude and occupational factors are important risk factors for brick tea-type fluorosis.


Assuntos
Doenças Ósseas/epidemiologia , Exposição Ambiental/efeitos adversos , Fluoretos/efeitos adversos , Fluorose Dentária/epidemiologia , Chá/efeitos adversos , Adulto , Altitude , Doenças Ósseas/induzido quimicamente , Criança , Estudos Transversais , Exposição Ambiental/estatística & dados numéricos , Fluoretos/administração & dosagem , Fluorose Dentária/etiologia , Humanos , Ocupações/estatística & dados numéricos , Prevalência , Fatores de Risco , Índice de Gravidade de Doença , Chá/química , Tibet/epidemiologia
9.
Clin Calcium ; 25(11): 1681-8, 2015 Nov.
Artigo em Japonês | MEDLINE | ID: mdl-26503874

RESUMO

Gastrectomy is undergone mainly in patients with gastric cancer. Bone diseases(osteoporosis and osteomalacia)caused by gastractomy are associated with weight loss, calcium and vitamin D inadequancy, and malnutrition. Most patients after gastrectomy have multile risk factors of bone diseases and subsequently are at a higher risk for fractures. In particular, sex hormone deficiency and aging enhance the risk for fractures. The management of bone diseases caused by gastraectomy include adequet intake of calcium, vitamin D and protein, sunlight exposure, and regular weight-bearing exercise, as well as non-smoking and avoiding excess alcohol drinking. The patients at a high risk for fractures shoud be treated with bisphosphonates.


Assuntos
Doenças Ósseas/prevenção & controle , Fraturas Ósseas/prevenção & controle , Gastrectomia/efeitos adversos , Densidade Óssea , Doenças Ósseas/complicações , Doenças Ósseas/epidemiologia , Suplementos Nutricionais , Terapia por Exercício , Humanos
10.
Eur. J. Ost. Clin. Rel. Res ; 10(2): 37-46, mayo-ago. 2015. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-141063

RESUMO

Introducción: El estreñimiento funcional es la patología más frecuente en Gastroenterología. Recientes estudios aseveran una presencia del 78% de dolores referidos al aparato locomotor de origen visceral. Objetivos: Evaluar la Maniobra Hemodinámica abdominal modificada (MHAM) en pacientes estreñidos a través del Umbral de dolor a la presión (UDP) en los niveles dorsales T10,T11 y T12, inclinometría para la flexión lumbar, el test de extensibilidad Sit and Reach y la valoración postural del paciente con el programa SAPO. Material y Métodos: Ensayo clínico aleatorizado controlado, a doble ciego en 20 pacientes (n=20); Grupo Control (GC: n=10) y Grupo Experimental (GE: n=10). Resultados: Algometría T11: en el GE la diferencia media fue de 1,05 kg (IC95%=0,501 a 1,603; p=0,001; d Cohen= 0,84). Algometría T12: en el GE la diferencia fue 1,23 kg (IC95%=0,499 a 1,969; p=0,002 significativa; d Cohen=0,89). Inclinometría T12: en el GE se produjo un incremento medio de 10,4º (IC 95%=7,59 a 13,21º; p<0,001; d Cohen=0,94).Test Sit and Reach: en el GE el aumento medio fue de 3,47cm (IC95%= 2,35 a 4,58 cm; p<0,001; d Cohen=0,77). Conclusiones: La aplicación de la Maniobra Hemodinámica Abdominal Modificada en pacientes con estreñimiento funcional genera cambios inmediatos aumentando la tolerancia al dolor en las vértebras T11 y T12, aumentando la flexión lumbar y mejorando la extensibilidad de los miembros inferiores (AU)


No dispoible


Assuntos
Constipação Intestinal/complicações , Constipação Intestinal/diagnóstico , Constipação Intestinal/patologia , Hemodinâmica/fisiologia , Doenças Ósseas/complicações , Doenças Ósseas/epidemiologia , Osteopatia/métodos , Osteopatia , Fotogrametria/métodos , Método Duplo-Cego , Medicina Osteopática/métodos , Medicina Osteopática/normas , Medicina Osteopática/tendências , Osteopatia/instrumentação , Osteopatia/tendências , Decúbito Dorsal , Análise de Variância
11.
Biomed Res Int ; 2015: 735615, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26000302

RESUMO

Hypovitaminosis D is a worldwide disorder, with a high prevalence in the general population of both Western and developing countries. In HIV patients, several studies have linked vitamin D status with bone disease, neurocognitive impairment, depression, cardiovascular disease, high blood pressure, metabolic syndrome, type 2 diabetes mellitus, infections, autoimmune diseases like type 1 diabetes mellitus, and cancer. In this review, we focus on the most recent epidemiological and experimental data dealing with the relationship between vitamin D deficiency and HIV infection. We analysed the extent of the problem, pathogenic mechanisms, clinical implications, and potential benefits of vitamin D supplementation in HIV-infected subjects.


Assuntos
Doenças Ósseas , Infecções por HIV/complicações , Infecções por HIV/epidemiologia , Deficiência de Vitamina D/complicações , Deficiência de Vitamina D/epidemiologia , Terapia Antirretroviral de Alta Atividade , Doenças Ósseas/complicações , Doenças Ósseas/epidemiologia , Infecções por HIV/tratamento farmacológico , Humanos , Prevalência , Fatores de Risco
12.
J Antimicrob Chemother ; 70(4): 1150-4, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25525197

RESUMO

OBJECTIVES: Nucleotide analogues may promote renal and bone toxicity. The aim of the present study was to evaluate markers of osteorenal toxicity in patients affected by hepatitis B virus-related chronic hepatitis treated with lamivudine plus adefovir who were switched to tenofovir. PATIENTS AND METHODS: We evaluated 60 consecutive patients at the time of the switch of treatment and after 1, 3, 6, 9 and 12 months. The mean baseline estimated glomerular filtration rate (eGFR) was 89.3 ± 19.0 mL/min/1.73 m(2). RESULTS: During the study period we observed a reduction in mean eGFR up to 6 months after switching to tenofovir, and this remained stable for the last two timepoints. At the end of study, the mean eGFR was 82.6 ± 21.5 mL/min/1.73 m(2), a reduction of 7.5%. The mean baseline proteinuria was 202.6 ± 237.6 mg/24 h. Microhaematuria was observed in 22.6% of patients and hypophosphataemia in 18.6%. After 1 month of tenofovir, we observed a worsening of serum phosphate and parathyroid hormone levels, haemoglobinuria and 24 h proteinuria. After 3 and 12 months of tenofovir, these data tended to recover to baseline levels. A total of 92.6% of patients at baseline had hypovitaminosis D. After supplementation with cholecalciferol, this percentage decreased significantly. We observed a reduced bone mineral density (BMD) in 52.7% of patients at baseline; this increased to 77.8% after 6 months of tenofovir, but at the last timepoint the percentage of patients with a reduced BMD had fallen to a level above the baseline. CONCLUSIONS: In conclusion, patients exposed to lamivudine plus adefovir showed relevant osteorenal damage. The switch to tenofovir provoked a slight reduction in eGFR that stabilized after 6 months. The reduced BMD at baseline did not worsen under tenofovir treatment.


Assuntos
Antivirais/efeitos adversos , Doenças Ósseas/induzido quimicamente , Doenças Ósseas/epidemiologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Hepatite B Crônica/tratamento farmacológico , Nefropatias/induzido quimicamente , Nefropatias/epidemiologia , Adenina/efeitos adversos , Adenina/análogos & derivados , Adenina/uso terapêutico , Adulto , Idoso , Antivirais/uso terapêutico , Doenças Ósseas/patologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia , Feminino , Taxa de Filtração Glomerular , Hematúria/induzido quimicamente , Hematúria/epidemiologia , Humanos , Hipofosfatemia/induzido quimicamente , Hipofosfatemia/epidemiologia , Nefropatias/patologia , Lamivudina/efeitos adversos , Lamivudina/uso terapêutico , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Organofosfonatos/efeitos adversos , Organofosfonatos/uso terapêutico , Proteinúria/induzido quimicamente , Proteinúria/epidemiologia , Deficiência de Vitamina D/induzido quimicamente , Deficiência de Vitamina D/epidemiologia
13.
Curr Opin Endocrinol Diabetes Obes ; 22(1): 35-40, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25517023

RESUMO

PURPOSE OF REVIEW: To update the reader's knowledge about the factors that influence bone mineral accrual and to review the advances in the assessment of bone health and treatment of bone disorders. RECENT FINDINGS: Maternal vitamin D status influences neonatal calcium levels, bone mineral density (BMD) and bone size. In turn, BMD z-score tends to track in childhood. These factors highlight the importance of bone health as early as fetal life. Dual-energy x-ray absorptiometry is the mainstay of clinical bone health assessment in this population because of the availability of appropriate reference data. Recently, more information has become available about the assessment and treatment of bone disease in chronically ill pediatric patients. SUMMARY: Bone health must become a health focus starting prenatally in order to maximize peak bone mass and to prevent osteoporosis-related bone disease in adulthood. Vitamin D, calcium and weight-bearing activity are the factors of key importance throughout childhood in achieving optimal bone health as BMD z-score tracks through childhood and into adulthood. Recent updates of the International Society for Clinical Densitometry focus on the appropriate use of dual-energy x-ray absorptiometry in children of all ages, including children with chronic disease, and on the treatment of pediatric bone disease.


Assuntos
Conservadores da Densidade Óssea/uso terapêutico , Doenças Ósseas/epidemiologia , Osso e Ossos/metabolismo , Cálcio da Dieta/uso terapêutico , Vitamina D/uso terapêutico , Absorciometria de Fóton , Densidade Óssea , Osso e Ossos/patologia , Criança , Fenômenos Fisiológicos da Nutrição Infantil , Pré-Escolar , Suplementos Nutricionais , Feminino , Humanos , Fenômenos Fisiológicos da Nutrição Materna
14.
Lancet Diabetes Endocrinol ; 2(4): 307-320, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24703049

RESUMO

BACKGROUND: Vitamin D insufficiency is associated with many disorders, leading to calls for widespread supplementation. Some investigators suggest that more clinical trials to test the effect of vitamin D on disorders are needed. METHODS: We did a trial sequential meta-analysis of existing randomised controlled trials of vitamin D supplements, with or without calcium, to investigate the possible effect of future trials on current knowledge. We estimated the effects of vitamin D supplementation on myocardial infarction or ischaemic heart disease, stroke or cerebrovascular disease, cancer, total fracture, hip fracture, and mortality in trial sequential analyses using a risk reduction threshold of 5% for mortality and 15% for other endpoints. FINDINGS: The effect estimate for vitamin D supplementation with or without calcium for myocardial infarction or ischaemic heart disease (nine trials, 48 647 patients), stroke or cerebrovascular disease (eight trials 46 431 patients), cancer (seven trials, 48 167 patients), and total fracture (22 trials, 76 497 patients) lay within the futility boundary, indicating that vitamin D supplementation does not alter the relative risk of any of these endpoints by 15% or more. Vitamin D supplementation alone did not reduce hip fracture by 15% or more (12 trials, 27 834 patients). Vitamin D co-administered with calcium reduced hip fracture in institutionalised individuals (two trials, 3853 patients) but did not alter the relative risk of hip fracture by 15% or more in community-dwelling individuals (seven trials, 46 237 patients). There is uncertainty as to whether vitamin D with or without calcium reduces the risk of death (38 trials, 81 173). INTERPRETATION: Our findings suggest that vitamin D supplementation with or without calcium does not reduce skeletal or non-skeletal outcomes in unselected community-dwelling individuals by more than 15%. Future trials with similar designs are unlikely to alter these conclusions. FUNDING: Health Research Council of New Zealand.


Assuntos
Doenças Ósseas/prevenção & controle , Suplementos Nutricionais , Neoplasias/prevenção & controle , Doenças Vasculares/prevenção & controle , Vitamina D/uso terapêutico , Vitaminas/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Doenças Ósseas/epidemiologia , Cálcio da Dieta/uso terapêutico , Determinação de Ponto Final , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Doenças Vasculares/epidemiologia
16.
Eur Rev Med Pharmacol Sci ; 17(9): 1218-32, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23690192

RESUMO

Hypovitaminosis D is a very common disorder, regarding both Western and developing countries. A growing amount of data over the last years have shown vitamin D deficiency to be high prevalent among HIV-positive subjects. In addition to "classic" risk factors, such as female sex, low dietary intake, dark skin pigmentation and low sun exposure, HIV-related factors, including immune activation and antiretroviral adverse effects, may affect vitamin D status. Even if both protease inhibitors and non-nucleoside reverse transcriptase inhibitors have been associated with low vitamin D levels, available evidences have failed to univocally associate hypovitaminosis D with specific antiretroviral class effects. Low vitamin D is known to have a negative impact not only on bone health, but also on neurocognitive, metabolic, cardiovascular and immune functions. Similarly to the general population, several studies conducted on HIV-infected subjects have associated hypovitaminosis D with a greater risk of developing osteopenia/osteoporosis and fragility fractures. Analogously, vitamin D deficiency has been described as an independent risk factor for cardiovascular disease and metabolic disorders, such as insulin resistance and type 2 diabetes mellitus. Last EACS guidelines suggest to screen for hypovitaminosis D every HIV-positive subject having a history of bone disease, chronic kidney disease or other known risk factors for vitamin D deficiency. Vitamin D repletion is recommended when 25-hydroxyvitamin D levels are below 10 ng/ml. Furthermore, it may be indicated in presence of 25OHD values between 10 and 30 ng/ml, if associated with osteoporosis, osteomalacia or increased parathyroid hormone levels. The optimal repletion and maintenance dosing regimens remain to be established, as well as the impact of vitamin D supplementation in preventing comorbidities.


Assuntos
Infecções por HIV/complicações , Infecções por HIV/epidemiologia , Deficiência de Vitamina D/epidemiologia , Deficiência de Vitamina D/etiologia , Terapia Antirretroviral de Alta Atividade/efeitos adversos , Doenças Ósseas/epidemiologia , Doenças Ósseas/etiologia , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/epidemiologia , Humanos , Fatores de Risco , Vitamina D/sangue , Vitamina D/uso terapêutico , Deficiência de Vitamina D/complicações , Deficiência de Vitamina D/diagnóstico , Deficiência de Vitamina D/terapia , Vitaminas/uso terapêutico
17.
Transplantation ; 95(12): 1479-84, 2013 Jun 27.
Artigo em Inglês | MEDLINE | ID: mdl-23572129

RESUMO

BACKGROUND: Renal transplant patients have been shown to have a higher risk of bone disease than the general population. The aim of this study was to examine vitamin D status, a modifiable risk factor in bone disease, in the renal transplant population in a northern climate. METHODS: This retrospective observational study included 331 subjects and analyzed demographic, biochemical, and medication information for associations with vitamin D. RESULTS: Of the study population, 45.3% were vitamin D deficient. The percentage of deficient subjects increases to 76.5% if those receiving supplementation are excluded. The mean daily dose of vitamin D was 1275 IU for sufficient patients. For every 1000 IU of vitamin D daily, the risk of deficiency is decreased by 40.3%. Time from transplantation had a significant positive association (P<0.001) in which every year out of transplantation decreased the risk of deficiency by 9.1%. Body mass index had a significant negative association (P=0.012) with vitamin D in which the risk of deficiency increased by 6% for each kilogram per meter squared. Ethnicity was found to be statistically significant on univariate analysis (P=0.034), with white patients having 9.1% decreased risk of deficiency. CONCLUSION: Despite a high rate of supplementation of vitamin D, close to half of the renal transplant population was still deficient. Those who were receiving over 1000 IU daily were more likely to be vitamin D sufficient. Early supplementation after transplantation along with higher doses for non-white patients or patients with a high body mass index may be warranted for normalization of vitamin D status.


Assuntos
Doenças Ósseas/epidemiologia , Transplante de Rim/efeitos adversos , Insuficiência Renal/complicações , Insuficiência Renal/epidemiologia , Deficiência de Vitamina D/epidemiologia , Adulto , Índice de Massa Corporal , Doenças Ósseas/etiologia , Clima , Suplementos Nutricionais , Feminino , Geografia , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência Renal/diagnóstico , Estudos Retrospectivos , Fatores de Risco , Luz Solar , Vitamina D/uso terapêutico , Deficiência de Vitamina D/complicações , Deficiência de Vitamina D/diagnóstico
19.
J Pediatr Endocrinol Metab ; 26(5-6): 469-75, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23423528

RESUMO

AIM: To evaluate the clinical and biochemical findings of the children and adolescents with vitamin D deficiency and insufficiency in order to determine the clinical and biochemical presentation differences between age groups. METHODS: This retrospective study included a review of medical reports of 543 patients (aged between 1-17 years) who were referred to our hospital between October 2011 and May 2012 with symptoms related to vitamin D deficiency or insufficiency. The patients were divided into four groups by age: 1-3 years (Group 1), 4-6 years (Group 2), 7-11 years (Group 3) and 12-17 years (Group 4). Patients diagnosed with vitamin D deficiency or insufficiency were evaluated as to their clinical and biochemical findings. RESULTS: Gender distribution were not statistically different between the four groups. The mean ages of Groups 1-4 were 1.9±0.7, 5.1±0.9, 8.9±1.3, 13.1±1.1, respectively. Major complaints on admission were muscle weakness (91%), low weight gain (failure to thrive) (89%), head deformity (frontal bossing) (35.6%), bone deformity (enlargement of wrist and ankles) (29.7%) for Group 1. Muscle weakness (76%) and low weight gain (failure to thrive) (68%) for Group 2. Leg and chest pain were the major symptoms in Group 3 (57% and 28%, respectively) and in Group 4 (26% and 55%, respectively) as well as high rates of obesity (31% and 63%). The biochemical findings of vitamin D deficiency mostly appeared in the first group who developed vitamin D deficiency due to the lack of vitamin D supplementation. However, in older children, the majority of the patients had low 25 hydroxyvitamin D (25 OHD) values without evidence of biochemical findings of osteomalacia. CONCLUSION: Depending on the degree of deficiency and insufficiency, and the age of the patients, the clinical and biochemical findings varied widely. Children under the age of 3 who either never received vitamin D supplementation or who had been receiving supplementation that was stopped too early were at a greater risk for developing clinically and biochemically proved vitamin D deficiency. In older children, low vitamin D levels mostly resulted in subtle complaints without abnormal biochemical findings.


Assuntos
Insuficiência de Crescimento/diagnóstico , Insuficiência de Crescimento/metabolismo , Debilidade Muscular/diagnóstico , Debilidade Muscular/metabolismo , Deficiência de Vitamina D/diagnóstico , Deficiência de Vitamina D/metabolismo , Adolescente , Doenças Ósseas/diagnóstico , Doenças Ósseas/epidemiologia , Doenças Ósseas/metabolismo , Criança , Pré-Escolar , Fácies , Insuficiência de Crescimento/epidemiologia , Feminino , Homeostase/fisiologia , Humanos , Lactente , Resistência à Insulina/fisiologia , Masculino , Debilidade Muscular/epidemiologia , Fatores de Risco , Deficiência de Vitamina D/epidemiologia
20.
Med Secoli ; 25(1): 85-99, 2013.
Artigo em Italiano | MEDLINE | ID: mdl-25807701

RESUMO

In 1982, some occasional excavations in the area corresponding to the ancient beach of Ercolano brought to light the rests of around 250 individuals, victims of the eruption of the Vesuvius. This exceptional recovery constitutes an essential patrimony for the reconstruction of the paleobiology and the paleopathology of the human populations in Roman epoch, in relationship not only to the style of life but also to the social and economic status. Notwithstanding the bone alterations due to the exposition to high temperature, the human remains present traces of illness. Among these we find rheumatic pathologies and arthrosis of the vertebral column. The high frequency of occupational markers (enthesopaties and sindesmopaties) suggests that the most part of the population (juveniles included) exercised hand work. Among the infectious pathologies we report cases of the tuberculosis and brucellosis.


Assuntos
Doenças Ósseas/história , Osso e Ossos/patologia , Brucelose/história , Mundo Romano , Tuberculose/história , Doenças Ósseas/epidemiologia , Doenças Ósseas/patologia , Brucelose/patologia , História Antiga , Humanos , Itália , Paleopatologia , Tuberculose/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA